Gilead’s 2 Hep C Drugs Likely to Face Some 30% Price Cut under “Huge Seller” Re-Pricing: Jiho Estimate

Gilead Sciences’s two big-selling hepatitis C treatments, Sovaldi (sofosbuvir) and Harvoni (ledipasvir + sofosbuvir), are expected to suffer a price slash of some 30% under a new special re-pricing rule in April, according to a Jiho estimate. As widely speculated...read more